Compass Pathways may be the first to benefit from an accelerated approval process.

Compass is opening its private listings to the industry — as long as you follow its rules. The brokerage, which has been waging a multi-front campaign on its ability to market listings without ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares sank 61% to $1.96, at one point ...

CIH disclosed a 51% stake in a Peerage-linked parent, including a 30-month repayment plan and a TPG cash put option.